HCA Q2 2024 rev $17.49B, EPS $5.53, raises FY guidance

HCA Healthcare, Inc.

2024-Q2 EPS reported $11.47 revenue$34,831,000,000

Revenue $17.492B (+10.3% YoY); net income $1.461B ($5.53 diluted EPS) vs $1.193B ($4.29).
Adjusted EBITDA $3.550B (+16.2% YoY); same facility admissions +5.8%, ER visits +5.5%.
FY2024 guidance raised: rev $69.75-71.75B (prev $67.75-70.25B), EPS $21.60-22.80 (prev $19.70-21.20).
Board declared quarterly dividend $0.66/share, payable Sept 30, record Sept 16.
Repurchased 4.217M shares at $1.367B in Q2; $4.228B remaining under buyback authorization.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.